Navigation Links
Proteon Therapeutics Completes $38M Equity Financing; Initiates Phase 1/2 Clinical Study of PRT-201 in Hemodialysis Patients and Signs Option Agreement With Major Pharmaceutical Company
Date:3/5/2009

WALTHAM, Mass., March 5 /PRNewswire/ -- Proteon Therapeutics, Inc., announced today that it has successfully completed a $38 million Series B equity financing, led by MPM Capital on behalf of the MPM Bio IV NVS Strategic Fund L.P. This announcement follows the initiation of a Phase 1/2 human clinical study of its lead product, PRT-201, in patients with end stage renal disease undergoing surgery for arteriovenous fistula (AVF) creation. Additionally, Proteon further bolstered its cash reserves by entering into an agreement with Novartis whereby Novartis has been granted an exclusive option to acquire Proteon following the successful completion of a Phase 2 clinical study of PRT-201 with a potential secondary right to a global license under pre-agreed conditions. Including the initial acquisition payment plus potential additional regulatory milestone payments, the deal with Novartis could exceed $550 million.

The Series B financing includes new investors, the MPM Bio IV NVS Strategic Fund L.P. and the Vectis Healthcare & Life Sciences Fund, along with existing investors TVM Capital, Skyline Ventures, Prism VentureWorks, Intersouth Partners and several of Proteon's original angel investors. Concurrent with the investment, Proteon also announced the addition of Dr. Steven St. Peter, Managing Director of MPM Capital, to the Proteon Therapeutics Board of Directors.

"Patients with kidney failure endure great suffering and frequent hospitalization due to vascular access complications. If successful, PRT-201 may improve medical outcomes and lower the associated cost of care," said Timothy P. Noyes, President and CEO of Proteon. "We greatly appreciate the continued support of our existing venture and angel investors, and we are excited to welcome MPM and Vectis as new investors." The combination of the Novartis option agreement and the closing of the Series B financing will allow Proteon to develop PRT-201 through Phase 2.


'/>"/>
SOURCE Proteon Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Proteon Therapeutics to Present New Data on PRT-201 at Transcatheter Cardiovascular Therapeutics (TCT) Annual Symposium in Washington, D.C., October 13, 2008
2. National Stem Cell Holding, Inc. Announces the Change of Its Name to Proteonomix, Inc.
3. Proteon Therapeutics Receives European Patent Covering New Method of Dilating Arteries and Veins
4. Proteon Therapeutics Appoints Experienced Biopharmaceutical Executive, Gregory D. Phelps to its Board of Directors
5. Proteon Therapeutics to Present at Annual Meeting of American Society of Nephrology in San Francisco on November 2, 2007
6. Proteon Therapeutics Completes $12 Million Financing and Hires CFO
7. Pharmexa and Affitech to Combine Operations to Create a New Antibody Therapeutics Company
8. ExonHit Therapeutics Invested Strongly in 2008 for Pivotal 2009 Results
9. Pearl Therapeutics Appoints Perry Karsen as Chief Executive Officer
10. CV Therapeutics Advises Stockholders to Take No Action at This Time in Response to Astellas Tender Offer
11. Cornerstone Therapeutics to Host Quarter and Year Ended December 31, 2008 Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... 28, 2015 RXi Pharmaceuticals Corporation (NASDAQ: ... developing innovative therapeutics, primarily in the areas of dermatology ... offering of 26 million units at a price to ... of approximately $10.4 million. Each unit consists of (i) ... purchase right to purchase 0.50 of a share of ...
(Date:5/28/2015)... , May 28, 2015  GenVec, Inc. (Nasdaq: ... Douglas J. Swirsky , will present a company ... 11 a.m. EDT on Thursday, June 4, 2015. ... Swirsky,s presentation will be available at the following link:  ... on GenVec,s website.  To access, visit www.genvec.com , ...
(Date:5/28/2015)... The Fertility Centers of New England is proud ... taken on a new and expanded role as Medical ... leadership, oversight and quality assurance for the practice. , ... team of experienced reproductive endocrinologists,” said Fertility Centers of ... “Her expertise and compassionate, individualized care have helped set ...
(Date:5/28/2015)... Whitehouse Laboratories is excited to announce ... partnership with PTI Inspection Systems. Whitehouse Labs and PTI ... custom-tailored method development and validation programs using the ... agreement includes a more formal program that facilitates cross ... This enables a more effective team approach, especially as ...
Breaking Biology Technology:RXi Pharmaceuticals Announces $10 Million Public Offering of Common Stock and Warrants 2RXi Pharmaceuticals Announces $10 Million Public Offering of Common Stock and Warrants 3GenVec To Present At The Jefferies Healthcare Conference 2Danielle Vitiello, MD of Fertility Centers of New England, Named New Medical Director 2Whitehouse Labs Renews & Enhances Partnership with PTI Inspection Systems 2Whitehouse Labs Renews & Enhances Partnership with PTI Inspection Systems 3
... Cellumen, Inc., the Cellular,Systems Biology Company, announced today ... Center for Toxicology Research (NCTR), a,research center of ... Cellumen will use its proprietary CellCiphr(R) toxicity risk,assessment ... toxicity,compounds including both failed and marketed drugs for ...
... ... -, ... stage biotechnology company committed to the,research and product discovery against life-threatening and ... Therapeutics has been led since its,inception in 2006 by James Sapirstein, RPh, ...
... SGX Pharmaceuticals,(Nasdaq: SGXP ) today announced that ... to the U.S. Food and Drug Administration for ... molecule for the treatment of relapsed and refractory ... for CML is Gleevec(R). Although Gleevec is a,highly ...
Cached Biology Technology:Cellumen to Collaborate With the NCTR of the FDA to Apply Cellular Systems Biology (CSB(TM)) to Predictive Toxicology 2Tobira Therapeutics Inc. Announces Senior Management Team 2Tobira Therapeutics Inc. Announces Senior Management Team 3SGX Pharmaceuticals Submits Investigational New Drug Application for SGX393 2SGX Pharmaceuticals Submits Investigational New Drug Application for SGX393 3
(Date:5/21/2015)... May 21, 2015 According ... Market by Solutions (Hardware, Software, Services), by Applications (Surveillance ... others), by End-Users (Military & Defense & Commercial) ... Thermal Imaging Market is expected to grow from ... 2020, at a Compound Annual Growth Rate (CAGR) ...
(Date:5/19/2015)... YORK , May 19, 2015  Technology is ... both internally and in the cloud. Passwords and their ... use of OTP and standards-based specifications such as those ... the outmoded use of passwords presents for BYOD, COPE, ... a unified biometric identity protocol. In ...
(Date:5/11/2015)... , May 11, 2015  Synaptics Incorporated ... human interface solutions, today announced the appointment of ... and Chief Financial Officer, reporting to Rick ... Synaptics, current Chief Financial Officer, Kathleen Bayless ... Mr. Ali brings extensive financial ...
Breaking Biology News(10 mins):Thermal Imaging Market Worth $9,998.9 Million by 2020 2Thermal Imaging Market Worth $9,998.9 Million by 2020 3Thermal Imaging Market Worth $9,998.9 Million by 2020 4HYPR Corp. Biometric Security Integration Kit Shields Applications and Devices Across the Internet of Things 2HYPR Corp. Biometric Security Integration Kit Shields Applications and Devices Across the Internet of Things 3Synaptics Appoints Wajid Ali as Senior Vice President and Chief Financial Officer 2
... rising from deep within the Earth are fueling the ... the rim of the 19,850-foot-high Socompa volcano in the ... team. The new study shows the emission ... vents near the summit of Socompa sustains complex microbial ...
... for example food, can be kept for a long ... University of Gothenburg, Sweden, is close to providing answers ... to carry out various biological functions. The protein,s level ... these functions is dependent on the amount of water ...
... March 3, 2009 -- Ben-Gurion University of the Negev ... technology, featuring two reversible panes that will save energy ... , "The ,Seasons Window, features the only glazing system ... or high radiant temperature near a window and reduces ...
Cached Biology News:Earth's highest known microbial systems fueled by volcanic gases 2Earth's highest known microbial systems fueled by volcanic gases 3Ben-Gurion University of the Negev researchers develop new reversible, green window technology 2
...
... the autofluorescent pigment lipofuscin accumulates in ... including neurons. The presence of lipofuscin ... fluorescence microscopy in the central nervous ... and emission spectra, which overlaps with ...
Purified anti-LAT...
Polyclonal Antibody to AHI1 / Jouberin...
Biology Products: